Actively Recruiting
Randomized Study Evaluating Oral Brepocitinib Safety and Efficacy for Adults With Cutaneous Sarcoidosis
Led by Priovant Therapeutics, Inc. · Updated on 2026-11-03
168
Participants Needed
44
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with cutaneous sarcoidosis, a condition affecting the skin. This phase 23 randomized, double-blind, placebo-controlled trial aims to study different doses of brepocitinib to understand how it impacts the diseases activity and morphology. The study is sponsored by Priovant Therapeutics, Inc. and focuses on measuring adverse events and improvements in skin condition over 16 weeks. Participants will be randomly assigned to receive one of several doses of oral brepocitinib or a placebo. The study is divided into two parts Part 1 compares two dose levels of brepocitinib against placebo, and Part 2 evaluates one dose level against placebo. Treatment lasts for 16 weeks, during which participants take the study drug or placebo orally. The trial uses a triple-blind design, meaning participants, investigators, and others involved do not know which treatment is being given. During the 16-week treatment period, participants will be regularly monitored for treatment-emergent adverse events and serious side effects using CTCAE v5.0 criteria. The main measurement of effectiveness is the reduction in the Cutaneous Sarcoidosis Activity and Morphology Instrument Activity CSAMI-A score from baseline to Week 16. Secondary measures include changes in CSAMI-A scores and the proportion of participants achieving low disease activity. Safety and treatment effects are closely observed, with the study completion planned for the end of 2029.
CONDITIONS
Brief Title
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Research Team
C
Clinical Trial Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here